Cue Biopharma (CUE)
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing injectable therapeutics designed to selectively engage and modulate disease-relevant T cells in the United States. Its pipeline includes CUE-401, a bifunctional fusion protein being studied preclinically to promote immune tolerance, and CUE-501, which is being developed for autoimmune disease through anti-viral T cell-mediated depletion of B cells. The company also has several mid-stage oncology programs, including CUE-101 for HPV-positive recurrent metastatic head and neck squamous cell carcinoma and CUE-102 for WT1-positive recurrent metastatic colorectal, gastric, ovarian, and pancreatic cancers. Cue Biopharma maintains collaboration and licensing arrangements with LG Chem, Ono Pharmaceutical, and Albert Einstein College of Medicine. Founded in 2014 and headquartered in Boston, Massachusetts, the company changed its name from Imagen Biopharma in October 2016.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CUE
|
$34.53
|
6.8% Upside
|
Fair
|
$115
|
255.8% Upside
|
Bargain
|
Good
|
—
|
—
|
—
|
0.0%
|
August 18, 2026
|
-6.9x
|
6.2x
|
4.1x
|
130 M
|
120.7 M
|
2.6%
|
90.4%
|
-8.8
|
—
|
126.0%
|
